US FDA panel backs Replimune skin cancer drug study data
REPL•FDA panel backs study results
July 30 (Reuters) - A panel of outside advisers to the FDA voted to back results from a trial studying Replimune's REPL.O drug for a type of skin cancer in a meeting on Thursday.
